MARKET

INAB

INAB

In8Bio, Inc.
NASDAQ
2.470
+0.090
+3.78%
After Hours: 2.500 +0.03 +1.21% 16:15 12/07 EST
OPEN
2.320
PREV CLOSE
2.380
HIGH
2.470
LOW
2.300
VOLUME
48.21K
TURNOVER
0
52 WEEK HIGH
7.25
52 WEEK LOW
1.380
MARKET CAP
60.52M
P/E (TTM)
-1.8164
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 6d ago
B. Riley Securities Downgrades IN8bio to Neutral, Lowers Price Target to $3
Benzinga · 11/11 11:39
--B. Riley Downgrades IN8bio to Neutral From Buy, Notes Limited Catalysts, Cash; Lowers Price Target to $3 From $9
--B. Riley Downgrades IN8bio to Neutral From Buy, Notes Limited Catalysts, Cash; Lowers Price Target to $3 From $9
MT Newswires · 11/11 07:57
IN8bio, Inc. - Common Stock Q3 EPS $(0.34) Down From $(0.25) YoY
Benzinga · 11/10 12:39
IN8bio To Present Early Data From Ongoing Phase 1 Study Of INB-100 At The 64th American Society of Hematology Annual Meeting
Benzinga · 11/03 13:44
IN8bio to Present at November Investor Conferences
NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced William Ho, CEO and co-...
GlobeNewswire · 11/01 11:30
PEDEVCO, VerifyMe And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones dipped by more than 450 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 09/30 12:49
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 09/15 12:26
More
About INAB
IN8bio, Inc. is a cell analysis solutions company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. The Company develops ex vivo-expanded and activated gamma-delta T cell candidates based upon its capabilities in gamma-delta T cell biology, genetic engineering and cell-type-specific manufacturing capabilities, DeltEx platform. Its lead product candidate, INB-200, is a genetically modified autologous gamma-delta T cell in Phase I clinical trial. Its INB-100, its off-the-shelf allogeneic DeltEx product candidate, was developed to demonstrate the safety of donor-derived expanded and activated gamma-delta T cells that do not undergo additional genetic modification. Its INB-400 is its allogeneic DeltEx DRI product candidate to treat solid tumor cancers, including newly diagnosed glioblastoma (GBM). Its INB-300 is a preclinical program focused on developing CAR-T-enabled DeltEx DRI product candidates.

Webull offers kinds of IN8BIO, Inc. stock information, including NASDAQ:INAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INAB stock methods without spending real money on the virtual paper trading platform.